AMOXIL VIALS FOR INJECTION 500MG
Active substance: AMOXICILLIN SODIUM
View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Amoxil Vials for Injection 500 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Amoxil Vials for Injection 500 mg contain 500 mg amoxycillin The amoxycillin is present as the sodium salt in Amoxil injections (each 1 g vial contains approximately 3.3 mmol of sodium).
3.
PHARMACEUTICAL FORM Amoxil Vials: vials containing sterile powder for reconstitution.
4
CLINICAL PARTICULARS
4.1
Therapeutic indications
Treatment of Infection: Amoxil is a broad spectrum antibiotic indicated for the treatment of commonly occurring bacterial infections such as: Upper respiratory tract infections Otitis media Acute and chronic bronchitis Chronic bronchial sepsis Lobar and bronchopneumonia Cystitis, urethritis, pyelonephritis
Bacteriuria in pregnancy Gynaecological infections including puerperal sepsis and septic abortion Gonorrhoea Peritonitis Intra-abdominal sepsis Septicaemia Bacterial endocarditis Typhoid and paratyphoid fever Skin and soft tissue infections In children with urinary tract infection the need for investigation should be considered. Prophylaxis of endocarditis: Amoxil may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis. Consideration should be given to official local guidance (e.g. national requirements) on the appropriate use of antibacterial agents. Susceptibility of the causative organism to the treatment should be tested (if possible), although the therapy may be initiated before the results are available. The wide range of organisms sensitive to the bactericidal action of Amoxil include: Gram-positive Streptococcus faecalis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus viridans Staphylococcus aureus (penicillin-sensitive) Clostridium species Corynebacterium species Bacillus anthracis Listeria monocytogenes Gram-negative Haemophilus influenzae Escherichia coli Proteus mirabilis Salmonella species Shigella species Bordetella pertussis Brucella species Neisseria gonorrhoeae Neisseria meningitidis Vibrio cholerae Pasteurella septica
4.2
Posology and method of administration
Treatment of infection: Adult dosage (including elderly patients): Injectable: 500 mg IM eight hourly (or more frequently if necessary) in moderate infections. (This dose may be given by slow IV injection if more convenient.) 1 g IV six hourly in severe infections. Children's dosage (up to 10 years of age): Injectable: 50-100 mg/kg body weight a day, in divided doses. Parenteral therapy is indicated if the oral route is considered impracticable or unsuitable, and particularly for the urgent treatment of severe infection. In renal impairment the excretion of the antibiotic will be delayed and, depending on the degree of impairment, it may be necessary to reduce the total daily dosage. Prophylaxis of endocarditis:
CONDITION ADULT'S DOSAGE (INCLUDING ELDERLY) CHILDREN'S DOSAGE NOTES
Dental procedures: prophylaxis for patients undergoing extraction, scaling or surgery involving gingival tissues and who have not received a penicillin in the previous month. (N.B. Patients with prosthetic heart valves should be referred to hospital - see below).
Patient not having general anaesthetic.
3 g Amoxil orally, 1 hour before procedure. A second dose may be given 6 hours later, if considered necessary.
Under 10: half adult dose. Under 5: quarter adult dose.
Patient having general anaesthetic: if oral antibiotics considered to be appropriate
Initially 3 g Amoxil orally 4 hours prior to anaesthesia, followed by 3 g orally (or 1 g IV or IM if oral dose not tolerated) as soon as possible after the operation.
1 g Amoxil IV or IM immediately before induction; with 500 mg orally, 6 hours later. Patient having general anaesthetic: if oral antibiotics not appropriate.
Note 1. If prophylaxis with Amoxil is given twice within one month, emergence of resistant streptococci is unlikely to be a problem. Alternative antibiotics are recommended if more frequent prophylaxis is required, or if the patient has received a course of treatment with a penicillin during the previous month. Note 2. To minimise pain on injection, Amoxil may be given as two injections of 500 mg dissolved in sterile 1% lignocaine solution (see Administration).
Dental procedures: patients for whom referral to hospital is recommended: a) Patients to be given a general anaesthetic who have been given a penicillin in the previous month. b) Patients to be given a general anaesthetic who have a prosthetic heart valve. c) Patients who have had one or more attacks of endocarditis.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM immediately prior to anaesthesia (if given) or 15 minutes prior to dental procedure. Followed by (6 hours later): 500 mg Amoxil orally.
Under 10: the doses of Amoxil should be half the adult dose; the dose of gentamicin should be 2 mg/kg.
See Note 2. Note 3. Amoxil and gentamicin should not be mixed in the same syringe. Note 4. Please consult the appropriate data sheet for full prescribing information on gentamicin.
Under 5: the doses of Amoxil should be quarter the adult dose; the dose of gentamicin should be 2 mg/kg.
Genitourinary Surgery or Instrumentation: prophylaxis for patients who have no urinary tract infection and who are to have genito-urinary surgery or instrumentation under general anaesthesia.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM, immediately before induction. Followed by (6 hours later): 500 mg Amoxil orally or IV or IM according to clinical condition. 1 g Amoxil IV or IM immediately before induction; 500 mg Amoxil IV or IM 6 hours later. Under 10: half adult dose.
See Notes 2, 3 and 4 above.
In the case of Obstetric and Gynaecological Procedures and Gastrointestinal Procedures routine prophylaxis is recommended only for patients with prosthetic heart valves. Surgery or Instrumentation of the Upper Respiratory Tract Patients other than those with prosthetic heart valves.
See Note 2 above. Note 5. The second dose of Amoxil may be administered orally as Amoxil Syrup SF.
Under 5: quarter adult dose.
Patients with prosthetic heart valves.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM, immediately before induction; followed by (6 hours later) 500 mg Amoxil IV or IM.
Under 10: the dose of Amoxil should be half the adult dose; the gentamicin dose should be 2 mg/kg.
See Notes 2, 3, 4 and 5 above.
Under 5: the dose of Amoxil should be quarter the adult dose; the dose of gentamicin should be 2 mg/kg.
Administration: Intravenous Injection, Intravenous Infusion, Intramuscular: Using vials for injection (See Section 6.6)
4.3
Contraindications Amoxil is a penicillin and should not be given to penicillin-hypersensitive patients. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics, e.g. cephalosporins.
4.4
Special Warnings and Precautions for Use Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of hypersensitivity to beta-lactam antibiotics (see Section 4.3). Erythematous (morbilliform) rashes have been associated with glandular fever in patients receiving amoxicillin. Prolonged use may also occasionally result in overgrowth of non-susceptible organisms. In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (see Section 4.9 Overdose). Amoxicillin has been reported to precipitate in bladder catheters after intravenous administration of large doses. A regular check of patency should be maintained.
Dosage should be adjusted in patients with renal impairment (see Section 4.2). Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sections 4.5 and 4.8). When prepared for intramuscular or direct intravenous injection, Amoxil should be administered immediately after reconstitution. The stability of Amoxil in various infusion fluids is given in the Package Enclosure Leaflet.
4.5
Interaction with other Medicinal Products and other Forms of Interaction Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with Amoxil may result in increased and prolonged blood levels of amoxicillin. In common with other antibiotics, amoxicillin may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives. Concurrent administration of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin (see sections 4.4 and 4.8). It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.
4.6
Pregnancy and lactation Use in pregnancy: Animal studies with Amoxil have shown no teratogenic effects. The product has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Amoxil may be considered appropriate when the potential benefits outweigh the potential risks associated with treatment.
Use in lactation: Amoxycillin may be given during lactation. With the exception of the risk of sensitisation associated with the excretion of trace quantities of amoxycillin in breast milk, there are no known detrimental effects for the breast-fed infant.
4.7
Effects on ability to drive and use machines Adverse effects on the ability to drive or operate machinery have not been observed.
4.8
Undesirable Effects The following convention has been utilised for the classification of undesirable effects:Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000,<1/100), rare (>1/10,000, <1/1000), very rare (<1/10,000) The majority of side effects listed below are not unique to amoxicillin and may occur when using other penicillins. Unless otherwise stated, the frequency of adverse events has been derived from more than 30 years of post-marketing reports.
Infections and infestations Very Rare: Mucocutaneous candidiasis
Blood and lymphatic system disorders Very rare: Reversible leucopenia (including severe neutropenia or agranulocytosis), reversible thrombocytopenia and haemolytic anaemia. Prolongation of bleeding time and prothrombin time (see section 4.4 Special Warnings and Precautions for Use
Immune system disorders
Very rare:
As with other antibiotics, severe allergic reactions, including angioneurotic oedema, anaphylaxis (see Section 4.4 - Special Warnings and Precautions for Use), serum sickness and hypersensitivity vasculitis. If a hypersensitivity reaction is reported, the treatment must be discontinued. (See also Skin and subcutaneous tissue disorders).
Nervous system disorders Very rare: doses. Hyperkinesia, dizziness and convulsions. Convulsions may occur in patients with impaired renal function or in those receiving high
Gastrointestinal disorders Clinical Trial Data Common: Uncommon: Diarrhoea and nausea. Vomiting.
Post-marketing Data Very rare: Antibiotic associated colitis (including pseudomembraneous colitis and haemorrhagic colitis).
Hepato-biliary disorders Very rare: ALT. Hepatitis and cholestatic jaundice. A moderate rise in AST and/or
The significance of a rise in AST and/or ALT is unclear.
Skin and subcutaneous tissue disorders Clinical Trial Data Common: Uncommon: Skin rash Urticaria and pruritus
Post-marketing Data Very rare: Skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis (AGEP)
(See also Immune system disorders).
Renal and urinary tract disorders Very rare: Interstitial nephritis, crystalluria (See Section 4.9 Overdose).
The incidence of these AEs was derived from clinical studies involving a total of approximately 6,000 adult and paediatric patients taking amoxicillin. 4.9 Overdose Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically with attention to the water/electrolyte balance. Amoxycillin crystalluria, in some cases leading to renal failure, has been observed (see Section 4.4 Special warnings and special precautions for use). Amoxycillin may be removed from the circulation by haemodialysis.
5.
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties Amoxil is a broad spectrum antibiotic. It is rapidly bactericidal and possesses the safety profile of a penicillin.
5.2
Pharmacokinetic properties Amoxil is well absorbed by the oral and parenteral routes. Amoxil gives good penetration into bronchial secretions and high urinary concentrations of unchanged antibiotic.
5.3
Preclinical safety data Not applicable.
6.
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Amoxil Injection: None
6.2
Incompatibilities Amoxil should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates, or with intravenous lipid emulsions. If Amoxil is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.
6.3
Shelf life
Injection Vials 24 months
6.4
Special precautions for storage Amoxil Vials for Injection should be stored in a cool, dry place. When prepared for intramuscular or direct intravenous injection, Amoxil should be administered immediately after reconstitution. The stability of Amoxil in various infusion fluids is dependent upon the concentration and temperature: stability times are given in the Package Enclosure Leaflet.
6.5.
Nature and contents of container Amoxil Vials for Injection: Clear Type I glass vials fitted with a chlorobutyl rubber bung and an aluminium overseal. 500 mg: packs of 5 or 10. Each pack carries instructions for use.
6.6
Instructions for use, handling and disposal
Intravenous Injection Dissolve 500 mg in 10 ml Water for Injections BP (Final volume=10.4 ml). Amoxil injection, suitably diluted, may be injected directly into a vein or the infusion line over a period of three to four minutes. Intravenous Infusion Solutions may be prepared as described for intravenous injections and then added to an intravenous solution in a minibag or in-line burette and administered over a period of half to one hour. Alternatively, using a suitable reconstitution device, the appropriate volume of intravenous fluid may be transferred from the infusion bag into the vial and then drawn back into the bag after dissolution. Intramuscular: 500 mg: Add 2.5 ml Water for Injections BP and shake vigorously (Final volume=2.9 ml). If pain is experienced on intramuscular injection, a sterile 1% solution of lignocaine hydrochloride or 0.5% solution of procaine hydrochloride may be used in place of Water for Injections. A transient pink colouration or slight opalescence may appear during reconstitution. Reconstituted solutions are normally a pale straw colour. ADMINISTRATIVE DATA 7. MARKETING AUTHORISATION HOLDER
Beecham Group plc Great West Road Brentford Middlesex TW8 9GS
Trading as: GlaxoSmithKline UK Stockley Park West Uxbridge Middlesex UB11 1BT
8.
MARKETING AUTHORISATION NUMBER(S) PL 00038/0222
9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION 14 September 1977 / 13 October 2003
10
DATE OF REVISION OF THE TEXT
04/01/2012
1
NAME OF THE MEDICINAL PRODUCT
Amoxil Vials for Injection 500 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Amoxil Vials for Injection 500 mg contain 500 mg amoxycillin The amoxycillin is present as the sodium salt in Amoxil injections (each 1 g vial contains approximately 3.3 mmol of sodium).
3.
PHARMACEUTICAL FORM Amoxil Vials: vials containing sterile powder for reconstitution.
4
CLINICAL PARTICULARS
4.1
Therapeutic indications
Treatment of Infection: Amoxil is a broad spectrum antibiotic indicated for the treatment of commonly occurring bacterial infections such as: Upper respiratory tract infections Otitis media Acute and chronic bronchitis Chronic bronchial sepsis Lobar and bronchopneumonia Cystitis, urethritis, pyelonephritis
Bacteriuria in pregnancy Gynaecological infections including puerperal sepsis and septic abortion Gonorrhoea Peritonitis Intra-abdominal sepsis Septicaemia Bacterial endocarditis Typhoid and paratyphoid fever Skin and soft tissue infections In children with urinary tract infection the need for investigation should be considered. Prophylaxis of endocarditis: Amoxil may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis. Consideration should be given to official local guidance (e.g. national requirements) on the appropriate use of antibacterial agents. Susceptibility of the causative organism to the treatment should be tested (if possible), although the therapy may be initiated before the results are available. The wide range of organisms sensitive to the bactericidal action of Amoxil include: Gram-positive Streptococcus faecalis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus viridans Staphylococcus aureus (penicillin-sensitive) Clostridium species Corynebacterium species Bacillus anthracis Listeria monocytogenes Gram-negative Haemophilus influenzae Escherichia coli Proteus mirabilis Salmonella species Shigella species Bordetella pertussis Brucella species Neisseria gonorrhoeae Neisseria meningitidis Vibrio cholerae Pasteurella septica
4.2
Posology and method of administration
Treatment of infection: Adult dosage (including elderly patients): Injectable: 500 mg IM eight hourly (or more frequently if necessary) in moderate infections. (This dose may be given by slow IV injection if more convenient.) 1 g IV six hourly in severe infections. Children's dosage (up to 10 years of age): Injectable: 50-100 mg/kg body weight a day, in divided doses. Parenteral therapy is indicated if the oral route is considered impracticable or unsuitable, and particularly for the urgent treatment of severe infection. In renal impairment the excretion of the antibiotic will be delayed and, depending on the degree of impairment, it may be necessary to reduce the total daily dosage. Prophylaxis of endocarditis:
CONDITION ADULT'S DOSAGE (INCLUDING ELDERLY) CHILDREN'S DOSAGE NOTES
Dental procedures: prophylaxis for patients undergoing extraction, scaling or surgery involving gingival tissues and who have not received a penicillin in the previous month. (N.B. Patients with prosthetic heart valves should be referred to hospital - see below).
Patient not having general anaesthetic.
3 g Amoxil orally, 1 hour before procedure. A second dose may be given 6 hours later, if considered necessary.
Under 10: half adult dose. Under 5: quarter adult dose.
Patient having general anaesthetic: if oral antibiotics considered to be appropriate
Initially 3 g Amoxil orally 4 hours prior to anaesthesia, followed by 3 g orally (or 1 g IV or IM if oral dose not tolerated) as soon as possible after the operation.
1 g Amoxil IV or IM immediately before induction; with 500 mg orally, 6 hours later. Patient having general anaesthetic: if oral antibiotics not appropriate.
Note 1. If prophylaxis with Amoxil is given twice within one month, emergence of resistant streptococci is unlikely to be a problem. Alternative antibiotics are recommended if more frequent prophylaxis is required, or if the patient has received a course of treatment with a penicillin during the previous month. Note 2. To minimise pain on injection, Amoxil may be given as two injections of 500 mg dissolved in sterile 1% lignocaine solution (see Administration).
Dental procedures: patients for whom referral to hospital is recommended: a) Patients to be given a general anaesthetic who have been given a penicillin in the previous month. b) Patients to be given a general anaesthetic who have a prosthetic heart valve. c) Patients who have had one or more attacks of endocarditis.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM immediately prior to anaesthesia (if given) or 15 minutes prior to dental procedure. Followed by (6 hours later): 500 mg Amoxil orally.
Under 10: the doses of Amoxil should be half the adult dose; the dose of gentamicin should be 2 mg/kg.
See Note 2. Note 3. Amoxil and gentamicin should not be mixed in the same syringe. Note 4. Please consult the appropriate data sheet for full prescribing information on gentamicin.
Under 5: the doses of Amoxil should be quarter the adult dose; the dose of gentamicin should be 2 mg/kg.
Genitourinary Surgery or Instrumentation: prophylaxis for patients who have no urinary tract infection and who are to have genito-urinary surgery or instrumentation under general anaesthesia.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM, immediately before induction. Followed by (6 hours later): 500 mg Amoxil orally or IV or IM according to clinical condition. 1 g Amoxil IV or IM immediately before induction; 500 mg Amoxil IV or IM 6 hours later. Under 10: half adult dose.
See Notes 2, 3 and 4 above.
In the case of Obstetric and Gynaecological Procedures and Gastrointestinal Procedures routine prophylaxis is recommended only for patients with prosthetic heart valves. Surgery or Instrumentation of the Upper Respiratory Tract Patients other than those with prosthetic heart valves.
See Note 2 above. Note 5. The second dose of Amoxil may be administered orally as Amoxil Syrup SF.
Under 5: quarter adult dose.
Patients with prosthetic heart valves.
Initially: 1 g Amoxil IV or IM with 120 mg gentamicin IV or IM, immediately before induction; followed by (6 hours later) 500 mg Amoxil IV or IM.
Under 10: the dose of Amoxil should be half the adult dose; the gentamicin dose should be 2 mg/kg.
See Notes 2, 3, 4 and 5 above.
Under 5: the dose of Amoxil should be quarter the adult dose; the dose of gentamicin should be 2 mg/kg.
Administration: Intravenous Injection, Intravenous Infusion, Intramuscular: Using vials for injection (See Section 6.6)
4.3
Contraindications Amoxil is a penicillin and should not be given to penicillin-hypersensitive patients. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics, e.g. cephalosporins.
4.4
Special Warnings and Precautions for Use Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of hypersensitivity to beta-lactam antibiotics (see Section 4.3). Erythematous (morbilliform) rashes have been associated with glandular fever in patients receiving amoxicillin. Prolonged use may also occasionally result in overgrowth of non-susceptible organisms. In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (see Section 4.9 Overdose). Amoxicillin has been reported to precipitate in bladder catheters after intravenous administration of large doses. A regular check of patency should be maintained.
Dosage should be adjusted in patients with renal impairment (see Section 4.2). Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sections 4.5 and 4.8). When prepared for intramuscular or direct intravenous injection, Amoxil should be administered immediately after reconstitution. The stability of Amoxil in various infusion fluids is given in the Package Enclosure Leaflet.
4.5
Interaction with other Medicinal Products and other Forms of Interaction Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with Amoxil may result in increased and prolonged blood levels of amoxicillin. In common with other antibiotics, amoxicillin may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives. Concurrent administration of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin (see sections 4.4 and 4.8). It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.
4.6
Pregnancy and lactation Use in pregnancy: Animal studies with Amoxil have shown no teratogenic effects. The product has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Amoxil may be considered appropriate when the potential benefits outweigh the potential risks associated with treatment.
Use in lactation: Amoxycillin may be given during lactation. With the exception of the risk of sensitisation associated with the excretion of trace quantities of amoxycillin in breast milk, there are no known detrimental effects for the breast-fed infant.
4.7
Effects on ability to drive and use machines Adverse effects on the ability to drive or operate machinery have not been observed.
4.8
Undesirable Effects The following convention has been utilised for the classification of undesirable effects:Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000,<1/100), rare (>1/10,000, <1/1000), very rare (<1/10,000) The majority of side effects listed below are not unique to amoxicillin and may occur when using other penicillins. Unless otherwise stated, the frequency of adverse events has been derived from more than 30 years of post-marketing reports.
Infections and infestations Very Rare: Mucocutaneous candidiasis
Blood and lymphatic system disorders Very rare: Reversible leucopenia (including severe neutropenia or agranulocytosis), reversible thrombocytopenia and haemolytic anaemia. Prolongation of bleeding time and prothrombin time (see section 4.4 Special Warnings and Precautions for Use
Immune system disorders
Very rare:
As with other antibiotics, severe allergic reactions, including angioneurotic oedema, anaphylaxis (see Section 4.4 - Special Warnings and Precautions for Use), serum sickness and hypersensitivity vasculitis. If a hypersensitivity reaction is reported, the treatment must be discontinued. (See also Skin and subcutaneous tissue disorders).
Nervous system disorders Very rare: doses. Hyperkinesia, dizziness and convulsions. Convulsions may occur in patients with impaired renal function or in those receiving high
Gastrointestinal disorders Clinical Trial Data Common: Uncommon: Diarrhoea and nausea. Vomiting.
Post-marketing Data Very rare: Antibiotic associated colitis (including pseudomembraneous colitis and haemorrhagic colitis).
Hepato-biliary disorders Very rare: ALT. Hepatitis and cholestatic jaundice. A moderate rise in AST and/or
The significance of a rise in AST and/or ALT is unclear.
Skin and subcutaneous tissue disorders Clinical Trial Data Common: Uncommon: Skin rash Urticaria and pruritus
Post-marketing Data Very rare: Skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis (AGEP)
(See also Immune system disorders).
Renal and urinary tract disorders Very rare: Interstitial nephritis, crystalluria (See Section 4.9 Overdose).
The incidence of these AEs was derived from clinical studies involving a total of approximately 6,000 adult and paediatric patients taking amoxicillin. 4.9 Overdose Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically with attention to the water/electrolyte balance. Amoxycillin crystalluria, in some cases leading to renal failure, has been observed (see Section 4.4 Special warnings and special precautions for use). Amoxycillin may be removed from the circulation by haemodialysis.
5.
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties Amoxil is a broad spectrum antibiotic. It is rapidly bactericidal and possesses the safety profile of a penicillin.
5.2
Pharmacokinetic properties Amoxil is well absorbed by the oral and parenteral routes. Amoxil gives good penetration into bronchial secretions and high urinary concentrations of unchanged antibiotic.
5.3
Preclinical safety data Not applicable.
6.
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Amoxil Injection: None
6.2
Incompatibilities Amoxil should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates, or with intravenous lipid emulsions. If Amoxil is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.
6.3
Shelf life
Injection Vials 24 months
6.4
Special precautions for storage Amoxil Vials for Injection should be stored in a cool, dry place. When prepared for intramuscular or direct intravenous injection, Amoxil should be administered immediately after reconstitution. The stability of Amoxil in various infusion fluids is dependent upon the concentration and temperature: stability times are given in the Package Enclosure Leaflet.
6.5.
Nature and contents of container Amoxil Vials for Injection: Clear Type I glass vials fitted with a chlorobutyl rubber bung and an aluminium overseal. 500 mg: packs of 5 or 10. Each pack carries instructions for use.
6.6
Instructions for use, handling and disposal
Intravenous Injection Dissolve 500 mg in 10 ml Water for Injections BP (Final volume=10.4 ml). Amoxil injection, suitably diluted, may be injected directly into a vein or the infusion line over a period of three to four minutes. Intravenous Infusion Solutions may be prepared as described for intravenous injections and then added to an intravenous solution in a minibag or in-line burette and administered over a period of half to one hour. Alternatively, using a suitable reconstitution device, the appropriate volume of intravenous fluid may be transferred from the infusion bag into the vial and then drawn back into the bag after dissolution. Intramuscular: 500 mg: Add 2.5 ml Water for Injections BP and shake vigorously (Final volume=2.9 ml). If pain is experienced on intramuscular injection, a sterile 1% solution of lignocaine hydrochloride or 0.5% solution of procaine hydrochloride may be used in place of Water for Injections. A transient pink colouration or slight opalescence may appear during reconstitution. Reconstituted solutions are normally a pale straw colour. ADMINISTRATIVE DATA 7. MARKETING AUTHORISATION HOLDER
Beecham Group plc Great West Road Brentford Middlesex TW8 9GS
Trading as: GlaxoSmithKline UK Stockley Park West Uxbridge Middlesex UB11 1BT
8.
MARKETING AUTHORISATION NUMBER(S) PL 00038/0222
9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION 14 September 1977 / 13 October 2003
10
DATE OF REVISION OF THE TEXT
04/01/2012
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
